Prof. Dr. Florian Bassermann
Academic Career and Research Areas
Florian Bassermann conducts research on the molecular pathophysiology of malignant diseases. The main focus of his work is on the aberrant mechanisms of ubiquitin-dependent signaling pathways, which play a pivotal role in the regulation of tumor relevant cellular processes, such as cell cycle regulation, DNA damage response, cell metabolism and programmed cell death. Insights from findings on such fundamental cellular pathways are further examined in translational studies to determine their importance for the pathogenesis and therapy of haematological tumors, in particular of B-cell neoplasias.
Bassermann studied medicine in Ulm, Munich and New York and received his PhD in 2002 from TUM. He subsequently stayed on at TUM to conduct research and clinical work. In 2006 he took up a postdoctoral position at New York University where he stayed until 2009. On his return to TUM he led a German Research Foundation (DFG) funded Emmy Noether junior research group, completed his training leading to German medical board certification in internal medicine and hematology/oncology, and acquired his postdoctoral teaching qualification (habilitation). In 2011 he was appointed to the position of senior physician and in 2015 he took up a tenure track professorship position at TUM.
- ERC Consolidator Grant (2015)
- Langener Science Award (2015)
- Theodor Frerichs Prize awarded by the German Society of Internal Medicine - DGIM (2015)
- Walther Flemming Medal awarded by the German Society of Cellular Biology (DGZ) (2010)
- Member of the Emmy Noether Program of the German Research Foundation - DFG (2009)
Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C, Keller U, Schmid B, Götze KS, Kuster B, Bassermann F: "Immunomodulatory drugs disrupt the CRBN-CD147/MCT1 axis to exert anti-tumor activity and teratogenicity". Nature Medicine. 2016; 22(7): 735-743.Abstract
Baumann U., Fernandez-Saiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F: „Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis“. Nature Medicine. 2014; 20(12): 1401-1409.Abstract
Fernández-Sáiz V, Targosz BS, Lemeer S, Eichner R, Langer C, Bullinger L, Reiter C, SlottaHuspenina J, Schroeder S, Knorn, AM, Kurutz J, Peschel C, Pagano M, Kuster B, Bassermann F: “SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma”. Nature Cell. Biol. 2013; 15(1): 72-81.Abstract
Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M: “The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA damage response checkpoint”. Cell. 2008; 134(2): 256-267.Abstract
Bassermann F, von Klitzing C, Muench S, Bai RY, Kawaguchi H, Morris SW, Peschel C, Duyster J: “NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry”. Cell. 2005; 122(1): 45-57.Abstract